Estimation of changes in the force of infection for intestinal and urogenital schistosomiasis in countries with Schistosomiasis Control Initiative-assisted programmes by French, M D et al.
RESEARCH Open Access
Estimation of changes in the force of
infection for intestinal and urogenital
schistosomiasis in countries with
schistosomiasis control initiative-assisted
programmes
Michael D. French1*, Thomas S. Churcher2, Joanne P. Webster1,2,11, Fiona M. Fleming1, Alan Fenwick1,
Narcis B. Kabatereine3, Moussa Sacko4, Amadou Garba5,9, Seydou Toure6, Ursuline Nyandindi7, James Mwansa8,
Lynsey Blair1, Elisa Bosqué-Oliva1,10 and Maria-Gloria Basáñez2
Abstract
Background: The last decade has seen an expansion of national schistosomiasis control programmes in Africa
based on large-scale preventative chemotherapy. In many areas this has resulted in considerable reductions in
infection and morbidity levels in treated individuals. In this paper, we quantify changes in the force of infection
(FOI), defined here as the per (human) host parasite establishment rate, to ascertain the impact on transmission of
some of these programmes under the umbrella of the Schistosomiasis Control Initiative (SCI).
Methods: A previous model for the transmission dynamics of Schistosoma mansoni was adapted here to S.
haematobium. These models were fitted to longitudinal cohort (infection intensity) monitoring and evaluation data.
Changes in the FOI following up to three annual rounds of praziquantel were estimated for Burkina Faso, Mali, Niger,
Tanzania, Uganda, and Zambia in sub-Saharan Africa (SSA) according to country, baseline endemicity and schistosome
species. Since schistosomiasis transmission is known to be highly focal, changes in the FOI at a finer geographical scale
(that of sentinel site) were also estimated for S. mansoni in Uganda.
Results: Substantial and statistically significant reductions in the FOI relative to baseline were recorded in the majority
of, but not all, combinations of country, parasite species, and endemicity areas. At the finer geographical scale assessed
within Uganda, marked heterogeneity in the magnitude and direction of the relative changes in FOI was observed that
would not have been appreciated by a coarser-scale analysis.
Conclusions: Reductions in the rate at which humans acquire schistosomes have been achieved in many areas of SSA
countries assisted by the SCI, while challenges in effectively reducing transmission persist in others. Understanding the
underlying heterogeneity in the impact and performance of the control intervention at the level of the transmission
site will become increasingly important for programmes transitioning from morbidity reduction to elimination of
infection. Such analyses will require a fine-scale approach. The lack of association found between programmatic
variables, such as therapeutic treatment coverage (recorded at district level) and changes in FOI (at sentinel site level) is
discussed and recommendations are made.
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Background
Recent years have seen a great expansion of national
schistosomiasis control programmes, mostly based on
large-scale preventive chemotherapy—also known as
mass drug administration (MDA)—with praziquantel,
resulting in significant successes in controlling infection
prevalence, intensity, and morbidity [1, 2]. What is not
yet clear is the benefit of such large-scale treatment to
the wider community via reductions in transmission.
These reductions will be manifested via a decrease in the
force of infection (FOI) which, for macroparasitic infec-
tions, is defined as the per capita rate at which a host
acquires new infections [3]. The precise understanding
of the FOI can be interpreted in a number of different
ways according to which stage of the parasites’ life-cycle
is of interest. The number of adult schistosomes within
a host can rarely be measured directly, so parasitological
surveys typically rely on faecal egg counts as a proxy for
parasite intensity. Therefore, routinely used diagnostic
tools cannot identify newly established parasites until
they reach patency and reproduce successfully.
For the purposes of this paper, the FOI is defined as
the rate at which new incoming worms establish into
adult parasites and reach patency (initiate detectable egg
production) in the human host population, and is con-
ceptually similar to the use of age-specific rates of re-
infection after treatment to measure the force of
infection used by other researchers [4]. However, this
may differ from the rate at which the host population is
infected by other parasitic stages, such as by cercariae
from the environment, which has been the approach
used historically via the use of snail studies or cercario-
metry [5–7].
Since schistosomiasis transmission models began to be
developed in earnest in the 1960s, significant advances
were the formulation of the reproduction number (in
prevalence models) to estimate rates of infection and
clearance [8, 9]; inclusion of mating probabilities and
transmission breakpoints (in intensity frameworks) to
examine how these influence the establishment, persist-
ence, and elimination of the infection [10–12]; incorpor-
ation of parasite latency and snail mortality [3, 12–14];
and the comparison of model outputs to field data to in-
vestigate heterogeneity in infection [15], among others.
Although some authors have favoured the use of
prevalence-based models [16], the use of (deterministic)
immigration-death, intensity frameworks was adopted in
[17], where such approaches describe the rate of change
of the number of schistosomes per person with respect
to time and host age. These were used to estimate the
rate of parasite acquisition (FOI), with this rate found to
be reliant on the intensity of incoming worms and the
load of already established parasites. Although such
models track the number of adult worms in human
hosts, they either calculate the prevalence of patent in-
fections in snails [18, 19], or assume that the schisto-
some population in snails and the parasite larval
population (miracidia; cercariae) in the environment are
at equilibrium given the disparity in the respective life-
spans [3]. The latter was the approach adopted by the
authors of the deterministic model EpiSchisto®[20], upon
which the code used in this study is based.
In a previous paper we used this approach to estimate
changes in the FOI relative to that at baseline, for co-
horts of individuals treated annually for three years with
praziquantel against intestinal schistosomiasis in Uganda
[21]. The extensive datasets of the Schistosomiasis Con-
trol Initiative (SCI), allowed regions within Uganda to be
classified according to underlying levels of average infec-
tion intensity at baseline measured in a cohort of
school-aged children and adults, namely, high endem-
icity: ≥400 eggs per gram of faeces [epg]; moderate en-
demicity: 100–399 epg, and low endemicity: 1–99 epg
[22]. Substantial and statistically significant reductions in
the FOI were observed following a single treatment
round in areas of low intensity of infection (76 % reduc-
tion; 95 % confidence interval [95 % CI]: 59–100 %), and
following two rounds in those of moderate (66 %; 95 %
CI: 26–87 %) and high (63 %; 95 % CI: 37–78 %) inten-
sity. It was concluded that the programme not only
benefited those individuals receiving treatment, but also
those who missed treatment, due to the ensuing de-
crease in environmental transmission. Demonstrating
quantitatively the impact of anthelmintic interventions is
crucial to ensure their sustainability, the engagement of
communities and funders, and the ultimate estimation
of their cost effectiveness [23].
Notwithstanding the usefulness of examining the im-
pact of interventions at relatively broad epidemiological
levels, these are likely to combine areas that differ in
terms of their transmission patterns. In reality, schisto-
somiasis is a focal disease, and considerable heterogen-
eity can often be observed in infection in neighbouring
communities, and even within communities [24]. In this
paper the earlier modelling approach is extended to cal-
culate relative changes in the FOI according to endem-
icity level in six countries that received SCI support
between 2003 and 2008 for both Schistosoma mansoni
and S. haematobium. The heterogeneity of such results
at a smaller, finer geographical scale is also explored,
using S. mansoni in Uganda as an illustrative example.
Methods
Datasets and cohorts
A full description of the data collection design for the
monitoring and evaluation (M&E) components of the
SCI treatment programmes is given elsewhere [2]. In
brief, data were collected for the six countries that
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implemented national or near-national treatment for
schistosomiasis (and soil-transmitted helminthiasis),
soon after the inception of the SCI in 2002. These were
three countries from West Africa (Burkina Faso, Mali,
Niger), and three from East Africa (Tanzania, Uganda,
Zambia), which provided datasets on either S. mansoni
or S. haematobium or both (Table 1 and Fig. 1). The
M&E approach was designed using a statistical frame-
work [2] to ensure that were a reduction in infection
levels occurring, such a reduction would be identifiable
and measurable [25].
There are two types of cohorts that comprise the SCI
data. Longitudinal cohorts consist of school-age children
in primary education (6–12 years or 7–12 years depend-
ing on age at first enrolment) followed up every year for
1 year (Zambia) or 2–3 years (the remaining countries)
(Table 1). Community cohorts focus on collecting data
from adults but also include children (age range of 4 –
88 years); these are designed to capture individuals lon-
gitudinally but due to the higher drop-out rate are often
of a cross-sectional design.
M&E cohorts are often assumed (either explicitly or
implicitly) to be representative of the wider community.
This may be true at baseline, where extra efforts are
often made to attract non-enrolled school-age children.
However, at follow-up, when (systematic) non-compliance
may play a significant role, those children more heavily in-
fected or too ill, engaged in work, or living in more distant
locations may not be able to attend school for re-
treatment. To investigate whether the longitudinal cohorts
were truly representative of the study populations of inter-
est, the baseline values of infection intensity and preva-
lence in those children who were followed for each year of
the study were compared with those of children who were
lost to follow-up [26] via normal distribution z-tests for
large samples [27]. The cohort retention rate was calcu-
lated as the proportion of individuals recruited into the
cohort at baseline who subsequently were positively iden-
tified at each of the following treatment rounds. Differ-
ences in the cohort retention rate with respect to age were
calculated using logistic regression with age as the
dependent variable and whether the individual was
retained in the cohort as the independent variable.
Sampling and descriptive statistics
For S. mansoni, infection intensity was estimated as the
arithmetic mean of either four Kato-Katz slides taken
across two consecutive days (two slides on day one and
two slides on day two, in Uganda, Tanzania, and
Zambia) or of two Kato-Katz slides taken on one day
(Mali, Niger, Burkina Faso). Infection intensity is
expressed as eggs per gram of faeces (epg) [28]. For S.
haematobium, infection intensity was estimated from ei-
ther a single urine filtration sample (Uganda, Tanzania,
Zambia, Mali, and Burkina Faso) or a double urine filtra-
tion from a single urine sample (Niger). Infection inten-
sity is expressed as eggs per 10 ml urine (e/10 ml) [22].
The relationship between adult worm burden and egg
output is poorly understood. This is in part caused by
variations in egg output by day, uneven distribution of
eggs in the excreta, imperfect sensitivity of diagnostic
methods, and the fact that only a proportion of the eggs
will exit the body [29–33]. However, attempts to define
the relationship between egg output and underlying
worm burden have concluded that there may be a posi-
tive and linear relationship for both S. mansoni [20] and
S. haematobium [34]. In contrast, analysis of the human
autopsy dataset of Cheever [35] suggested some measure
of negative density dependence in S. mansoni [36]. In
the present study, and for parsimony, a density-
independent relationship was assumed between female
worm burden and egg output, with each S. mansoni fe-
male producing on average of 5.26 epg [20], and each S.
haematobium female a mean of 3.60 e/10 ml [34].
Arithmetic means of infection intensity were used as
measures of central tendency [37], and their ninety five
percent confidence intervals (95 % CI) were calculated
using the normal approximation for large sample sizes
[27]. Point estimates of prevalence of infection and cat-
egories of infection (as described below) were also calcu-
lated and the normal approximation to the binomial
distribution was used to estimate their 95 % CI given the
large sample sizes available [27]. All statistical analyses
were carried out in the freely available software R [38].
Endemicity levels
To follow the same methodology for categorization of
endemicity of French et al. [21], the datasets were classi-
fied into areas of low, moderate and high underlying en-
demicity, based on the average infection intensity for
each sentinel site (school/community) at baseline, prior
to large-scale implementation of SCI-supported prazi-
quantel treatment programmes (although the possibility
that there had been previous, smaller-scale ad-hoc treat-
ment programmes cannot be totally discounted). Intes-
tinal schistosomiasis areas were allocated into high
(≥400 epg), moderate (100–399 epg) and low (1–99 epg)
infection intensity areas as described above. For urogeni-
tal schistosomiasis, areas they were classified into high
(≥50 e/10 ml) and low (1–49 e/10 ml) intensity areas
[22]. In both Mali and Tanzania the numbers of highly-
infected S. mansoni sentinel sties was low, and so these
were combined into a single high/moderate category.
Mathematical modelling
Schistosoma mansoni
Full details of the population dynamics model for S.
mansonican be found in French et al. (2010) [21] and in
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Table 1 Summary of longitudinal cohorts in three West African and three East African countries selected to receive assistance by the Schistosomiasis Control Initiative for
implementation of preventive chemotherapy programmes against schistosomiasis (and soil-transmitted helminthiasis)
Country Species Cohort Size
at Baseline
(No. schools)
BL Year Tx BL FY1 Year, Numbers,
(Follow-up rate),
Number of schools
Tx FY1 FY2 Year, Numbers,
(Follow-up rate),
Number of schools
Tx FY2 FY3 Year, Numbers,
(Follow-up rate),
Number of schools
Tx FY3 Age-range of
school
cohorts at
baseline
Proportion
of females
at BL (%)
Relevant
Publications
West Africa
Burkina
Faso
S. haematobium 1,422 (16
schools)
2004 Y 2005, 996 (70.0 %) 16
schools
N 2006, 770 (54.1 %) 16
schools
Y 2007, 564 (39.7 %)
15 schools
N 6-12 46.6 [2, 90, 91, 93]
Mali S. mansoni & S.
haematobium
3,599 (33
schools)
Mar-Jun
2004
Y May-Jun 2005 and
Apr – May 2006 1995
(55.4 %) 24 schools
Y Mar-Apr 2006 and
May-June 2007 (1511
(42.0 %) 27 schools
Y ND Y 7-14 49.9 [2, 26, 90, 91]
Niger S. haematobium 1,656 (8
schools)
Oct-Nov
2004 and
Mar-May
2005
Y Oct-Dec 2005 and
Mar-Apr 2006,1440
(87.0 %) 8 schools
Y Nov-Dec 2006 and
Jan-May 2007, 1193
(72.0 %) 8 schools
Y ND x 7,8,11 45.5 [2, 82, 90,
91, 94]
East and Southern Africa
Tanzania S. mansoni & S.
haematobium
3,145 (20
schools)
2005 Y 2006, 2235 (71.1 %)
19 schools
Y - N 2008, 1076 (34.2 %)
14 schools
N 7-12 56.9 [2, 92]
Uganda S. mansoni 4,351 (37
schools)
2003 Y 2004, 2815 (64.7 %)
37 schools
Y 2005, 1871 (43.0 %)
37 schools
Y 2006, 1156 (26.6 %)
33 schools
Y 6-8, 11 49.1 [1, 2, 92, 95]
Zambia S. mansoni & S.
haematobium
2,689 (22
schools)
Jul-Aug 05
and May –
Jun 06
Y Sep 2006 and May-
Jun 2007, 1633
(56.9 %) 21 schools
Y - N - x 7-12 53.4 [2, 92]
BL baseline, Tx treatment round, FY1 follow-up year 1, FY2 follow-up year 2, FY3 follow-up year 3, Y treatment received, N treatment not received, ND not done
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the supplementary information of that paper. These au-
thors modified an earlier framework presented by Chan
et al. [20] known as EpiSchisto®. In turn, EpiSchisto® was
based on previous work by Anderson and May [3, 17]
developing the use of immigration-death models. The
rate of change in mean adult S. mansoniworm burden
(M) (after the conversion from egg output to adult
female burden given previously of 5.26 epg per mated
female worm) with respect to host age (a) and time (t)
can be described by the following immigration-death
equation,
∂M a; tð Þ
∂t
þ ∂M a; tð Þ
∂a
¼ Λ að Þ−μMM a; tð Þ; ð1Þ
where Λ(a) is the net FOI at age a, and μM is the per
worm death rate of established (mature) adult worms. In
turn, Λ(a) is given by Eq. 2,
Λ að Þ ¼ λBζPτ að Þ: ð2Þ
Here, λB is the average underlying baseline FOI per
person, ζP is the relative to baseline ratio of the average
FOI after each round of treatment, with subscript P indi-
cating the number of rounds of praziquantel treatments
received, and the function τ(a) describes the (dimension-
less) age-specific contact function normalized over the
total host population. In order to use this continuous
function of age in the modelling process, the human
population is partitioned into n age groups each of width
1 year and mid-value a1 through an so that n = 60 and
the upper end of the of the n-th class is 60 years, with ai
denoting the i-th age group,
τ aið Þ ¼ ρ aið ÞXai¼n
ai¼1
ρ aið Þ
: ð3Þ
The function ρ(ai) represents the relative contact rates
distributed over age, and following Chan et al. (1995)
[39] it has equation,
ρ aið Þ ¼ ai e− βaið Þ
2 þ c : ð4Þ
The expression for ρ(ai) depends on two shape param-
eters, namely β and c, which together determine its
functional form with host age. (Further details can be
found in Supplementary Protocol S2 of [21].) The func-
tion Λ(a) denotes the yearly average number of (egg-
producing) worms acquired per person of age a and
comprises the product of the contact rate with infective
stages, the probability of infection upon contact, and the
average population of cercariae in the environment; in-
formation relating to the number of contacts per unit
time is subsumed within λB. We are not focussing on es-
timating absolute values of FOI but the relative changes
at each point of follow-up. It is assumed that praziquan-
tel instantaneously reduces the adult worm burden of S.
mansoni by 95 % in all treated hosts [40].
Fig. 1 Map of Africa showing: those SCI-assisted countries that provided datasets included in this study, species of schistosome found in each,
cohort sizes, and year of commencement of control programme
French et al. Parasites & Vectors  (2015) 8:558 Page 5 of 18
At baseline (prior to treatment), ζ0 = 1, and at follow-
up years 1, 2, and 3 (FY1, FY2 and FY3), ζ1, ζ2, and ζ3
indicate the ratio of the FOI relative to that at baseline,
respectively, when data for all three follow-up years were
available (e.g. Mali, Uganda). When follow-up data were
available for one or two consecutive years after baseline
(e.g. Zambia), the changes in the FOI were estimated as
described for these years. For Tanzania, treatment was
distributed at baseline and at FY1, but not at FY2 or
FY3; however, evaluation was conducted at FY3, so an
average change in the FOI for FY2 and FY3 is reported
here. A value of ζP lower or greater than 1 indicates, re-
spectively, a reduction or an increase in the FOI from
baseline, and a statistically significant reduction or in-
crease is indicated when the entire range of the confi-
dence interval lies, respectively, belowor above 1.
Confidence intervals for these parameters were esti-
mated as outlined below.
To understand how the overall changes in the FOI at
coarse-grain, macroepidemiological levels compared
with those taking place at a fine-grain scale (which are
more likely to correspond to individual transmission
zones), changes in the FOI were also estimated separ-
ately for each of 32 Ugandan sentinel sites with longitu-
dinal data and are reported where the sample size > 20
individuals (Fig. 2).
This dataset was also used to examine whether any
programmatic variables were statistically associated with
the FOI. A multivariate linear regression model incorp-
orating random effects was used with baseline intensity
of infection, treatment coverage and cohort retention
rate at each time point as the covariates, and the
Fig. 2 Map of Uganda showing results from baseline prevalence mapping of intestinal schistosomiasis in the country. The three main areas of
schistosomiasis transmission are situated along the shores of Lake Victoria, Lake Albert, and Albert Nile. The three levels of Schistosoma mansoni
endemicity at baseline are represented by closed circles: high (≥400 epg, violet); medium (100–399 epg, purple), and low (1–99 epg, pale pink)
transmission. Figure reproduced with permission from Zhang et al. (2007)
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absolute FOI at each sentinel site and time point as the
dependent variable. Therapeutic treatment coverage (the
proportion of people treated) was available only at the
district level (not at the sentinel site level) and was cal-
culated by dividing the number of people treated (taken
from treatment registers) by the targeted number in
each district (derived from census figures with a correc-
tion for population growth rates) (unpublished data).
The random effects of district were included in order to
control for any geographical clustering at this level [27].
Regression analyses were carried out at each of the three
follow-up time points, and were weighted by the number
of individuals at each sentinel site. The most parsimoni-
ous yet adequate model was chosen by comparing
Akaike Information Criterion (AIC) scores [41]. P-values
were considered significant at the 0.05 level.
Schistosoma haematobium
The model described in Eqs. 1, 2, 3 and 4 above was
modified so the number of eggs (per 10 ml urine) pro-
duced per adult female worm was set to 3.60 [35], and
the efficacy of praziquantel to 99 % [42]. This assumed
efficacy was shown to provide a better fit to the data
(see next subsection for a description of fitting ap-
proach) for the most complete S. haematobium dataset
(that of Burkina Faso; log-likelihood ratio test statistic =
12.54, p-value of χ2 < 0.001) and was retained for all S.
haematobium areas. This assumption is conservative
with regards to estimates of reduction in the FOI follow-
ing chemotherapy, i.e. the larger the assumed proportion
of parasites killed with treatment, the greater the
reinfection rate would need to be for parasite load to
return to observed levels. Schistosoma haematobium-
parameterised models were fitted to data from Burkina
Faso and Tanzania (three consecutive years of follow-up),
Mali and Niger (two years), and Zambia (one year).
Fitting Approach
The cross-sectional cohorts at baseline consisted of both
children and adults in order to provide the profile of
age-related infection intensity for each schistosome spe-
cies, endemicity area, and country. The age-stratified
model of Eqs. 1, 2, 3 and 4 was fitted simultaneously to
the longitudinal cohorts and the cross-sectional baseline
data using maximum likelihood estimation of the pa-
rameters of interest. The model was fitted to individual
host data (taking into account the high degree of para-
site overdispersion observed and estimated in each data-
set (see below and SI)) to estimate the following: the
baseline FOI, λB, the two shape parameters of the con-
tact function (ββ and c– Eq. 4), and the change in the
annual FOI after each round of chemotherapy (ζ1, ζ2,
and ζ3) relative to that at baseline. Uncertainty around
the parameters was estimated using the Fisher Informa-
tion Matrix [43].
The multi-dimensional parameter space was explored
using the Latin Hypercube sampling method [44, 45]. As
part of this fitting approach, the infection intensity ob-
servations of individuals were compared to the model-
derived, age-specific mean intensity of infection. Ninety
five percent confidence intervals around each of the pa-
rameters were calculated using the Fisher Information
Matrix [43]. Confidence intervals around the model out-
put (mean egg output) were estimated by re-running the
model and randomly selecting parameters from within
their 95 % CI bounds. Runs which generated likelihood
values not statistically significantly different from the
best fit run (tested using a Χ2 distribution with the ap-
propriate degrees of freedom) were used to construct
95 % CI around the model outputs [46]. The max-
imum and minimum mean egg output at each time-
point from these runs constituted the upper and
lower confidence intervals respectively.
The FOI is a dynamic entity, decreasing immediately
after treatment and increasing in inter-treatment pe-
riods. Therefore, the estimated values correspond to an
average across the relevant periods (each period being
one year for annual treatment unless otherwise stated)
and were corrected for the ageing of the cohort. Given
that these are longitudinal cohorts (with no replacement
of the youngest ages), the average age of participants will
inevitably increase, and schistosomiasis infection inten-
sity is known to be strongly dependent on host age [17]
with an increase in exposure typically experienced by
children between the ages of 5 – 15 years. Therefore, the
fitted mathematical model takes this into account by
allowing the age of the cohort to increase over time. Not
correcting for age can lead to underestimates of the FOI
reductions (or overestimates if the FOI increases) [21].
Model-derived changes in the average infection inten-
sity were calculated to help understand the impact of
treatment. Of particular importance are the estimated
changes in the proportion of individuals harbouring high
infection intensity (defined as the prevalence of hosts
excreting ≥400 epg for schistosomiasis mansoni and ≥50
e/10 ml for schistosomiasis haematobium), as those indi-
viduals are deemed to be the ones more likely to develop
and suffer morbidity [47], though even light infections can
be associated with significant morbidity [48].
Models were parameterized using parasite overdisper-
sion values calculated from prevalence-intensity relation-
ships for each endemicity area, parasite species, and
country (data not shown). Overdispersion of schistosome
distribution among hosts was assumed to be reasonably
approximated by the negative binomial distribution, with
the value of the overdispersion parameter (denoted by k,
an inverse measure of the strength of overdispersion),
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allowed to vary with the mean intensity of infection fol-
lowing either a linear (k = k0 + k1m), or a power function
(k = k0 + k1m
k2), where m denotes the arithmetic mean in-
tensity of infection [49], measured in epg or e/10 ml.
Ethical Approval
Data used for the analysis in this paper were collected as
part of the routine monitoring and evaluation activities
of the countries’ schistosomiasis control programmes.
Ethical approval for this was provided by Imperial Col-
lege Research Ethics Committee (ICREC_8_2_2, EC No.
03.36, R&D No. 03/SB/003E) and by the ethical review
boards of the Ministries of Health of the respective en-
demic countries.
Results
Cohort representativeness
A comparison between the baseline values of infec-
tion intensity and prevalence of heavy infection in
those individuals in the longitudinal cohort and those
lost to follow-up was conducted using the most ex-
tensive datasets, namely the cohorts for S. mansoni in
Uganda and for S. haematobium in Burkina Faso
(Fig. 3). In Uganda (Fig. 3a and b) the intensity of in-
fection was 29 % higher in those children who were
lost to follow-up (301 epg [95 % CIs: 271, 330 egg]
vs. 233 epg [95 % CIs: 205, 261], Z = 3.27, p-value =
0.001), driven primarily by a significant difference in
the egg counts of high intensity infections (27.2 %
higher; 843 epg [95 % CIs: 755, 930 egg] vs.663 epg
[95 % CIs: 574, 752 egg], Z = 2.82, p-value = 0.005).
However, there were no significant differences in the
prevalence of heavy infection between the two groups
(10.1 % higher in those lost to follow-up; 18.2 %
[95 % CIs: 16.7 %, 19.8 %] vs.16.6 % [95 % CIs:
14.8 %, 18.3 %], Z = 1.41, p-value = 0.16).
In Burkina Faso, no significant differences were ob-
served in infection intensity between those in the longi-
tudinal cohort, and those who were lost to follow-up.
With regard to the prevalence of heavy infection, there
was a non-significant higher prevalence in those lost to
follow-up in high intensity areas (33.9 % vs. 29.8 %, Z =
1.61, p-value = 0.10), and a statistically significantly lower
prevalence in low intensity areas (1.09 % vs. 4.08 %, Z =
2.21, p-value = 0.02).
There was no significant difference in the cohort
retention rate with respect to age in Uganda (logistic
regression, coefficient = −0.0085, Z = −0.506, p-value =
0.61). However, in Burkina Faso the retention rate
was statistically significantly and negatively associated
with age (coefficient = −0.1165, Z = −2.888, p-value =
0.004).
Changes in relative FOI with treatment
The relative changes in the FOI following successive treat-
ment rounds for each country, schistosome species, and
baseline endemicity areas are shown in Tables 2 and 3.
Schistosoma mansoni
Reductions in the FOI of S. mansoni in Uganda at a
macroepidemiological level have been estimated previ-
ously [21]. In summary, large and statistically significant
reductions were observed across all three infection in-
tensity areas –following one round in low intensity areas
(76 % reduction), and following two rounds in moderate
(66 % reduction) and high (63 % reduction) intensity
areas (Table 2). A similar situation was observed in Mali,
with substantial and significant reductions following two
rounds of treatment in low (82 % reduction) and high/
moderate intensity areas (40 %). This contrasts with
Tanzania where large increases in the FOI were observed
following one round of treatment (although a second
round resulted in sizeable reductions in low intensity
areas). Modest increases in the FOI were observed in
Zambia, both in the moderate and low intensity areas.
Schistosoma haematobium
In Burkina Faso, very extensive reductions in the FOI
were observed for S. haematobium, even following just a
single round of treatment (Table 3), with infection and
transmission levels dropping to virtually zero. Here,
there was no treatment at FY1 so the values of ζ1 (1.3
and 0.5 %) and ζ2 (12.4 and 25.3 %) represent the relative
ratio of the FOI one and two years after a single treat-
ment round. Even after a two-year treatment gap, re-
infection levels were markedly suppressed (close to
100 % reduction in high and low intensity areas in the
first year; 88 and 82 % respectively in the second year).
In Mali there were marked and statistically significant
reductions following one round of treatment in high in-
tensity areas, and following two rounds in low intensity
areas. In Niger reductions were modest (and not statisti-
cally significant) in high intensity areas, and considerable
and statistically significant in low intensity areas. In
Tanzania there was a 50 % reduction following one and
two rounds of treatment, which increased to 65 % fol-
lowing three rounds. Zambia presents a more confusing
picture; there was a relatively small reduction in high in-
tensity areas (27 %) following one round of treatment,
but a large increase in the FOI in low intensity areas
(more than twice the baseline value).
Heterogeneity in changes in the FOI at a finer
geographical scale
Changes in the FOI for each of the 32 sentinel sites from
Uganda are displayed in Table 4. Heterogeneity was ob-
served particularly in high intensity areas, where the FOI
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following one treatment round—as a proportion of that
at baseline—ranged from 0.179 (i.e. an 82.1 % reduction)
to 1.993 (i.e. a nearly twice as large a value as that at
baseline). This variation may be due to true heterogen-
eity between the sites or the impact of small statistical
size in some areas.
Significant increases in the FOI were observed in
some sentinel sites/schools following treatment, al-
though as may be expected the number of such sites
diminished with successive treatment rounds. In
Table 4, changes in the FOI are reported together
with changes in the intensity of infection; there were
a
dc
b
Fig. 3 Differences in infection markers between those individuals followed up in the longitudinal cohort for all years (red bars), and those lost to
follow-up (blue bars): a Mean infection intensity of Schistosoma mansoni in Uganda at baseline; b Prevalence of heavy intensity (≥400 epg) of S.
mansoni in Uganda at baseline; c Mean infection intensity of S. haematobium in Burkina Faso at baseline; d Prevalence of heavy intensity (≥50
eggs/10 ml urine) of S. haematobium in Burkina Faso at baseline. P-Values are stated where differences are statistically significant (P≤ 0.05), otherwise
they are omitted
Table 2 Relative (to baseline) changes in the force of infection (FOI) and their 95 % confidence intervals estimated at the point of
monitoring (one or two years) after each round of preventive chemotherapy with praziquantel for Schistosoma mansoni areas
Country BL Infection Intensity
Category
Number in
cohort (n)
BL infection
Intensity (epg)
BL FOI (wppy) FY1 ζ1 FY2 ζ2 FY3 ζ3
Mali High/Medium 215 452.75 16.35 0.97 [0.45, 1.92] 0.60 [0.41, 0.97]a NA
Mali Low 937 23.55 5.45 0.68 [0.45, 0.92]a 0.18 [0.09, 0.41]a NA
Tanzania High/Medium 290 400.38 18.26 3.61 [1.23, 5.04]b 2.03 [0.75, 3.22]
Tanzania Low 769 11.06 0.44 2.41 [1.23, 3.77]b 0.35 [0.15,0.78]a
Uganda High 262 766.04 30.00 0.78 [0.46, 1.50] 0.37 [0.22, 0.63]a 0.37 [0.19, 0.86]a
Uganda Medium 235 231.69 10.02 1.04 [0.49, 2.00] 0.34 [0.13, 0.74]a 0.46 [0.17, 1.06]
Uganda Low 600 33.54 1.69 0.24 [0, 0.61]a 0.32 [0.06, 0.64]a 0.20 [0.04, 0.43]a
Zambia Medium 83 326.8 14.80 1.28 [0.52, 3.43] NA NA
Zambia Low 1362 9.13 0.35 1.26 [0.89, 2.01] NA NA
FOI: force of infection expressed as the mean number of adult female parasites acquired per person per year; epg: eggs per gram of faeces; wppy: worm pairs per
person per year; BL: baseline; FY1: follow-up year 1; FY2: follow-up year 2; FY3: follow-up year 3; ζ1, ζ2, ζ3: the relative change in the FOI at FY1, FY2, FY3 respectively,
expressed as a proportion of that at baseline; asignificant decreases in FOI from baseline; bsignificant increases in FOI from baseline: NA: not available. In Tanzania there
was no treatment or survey at FY2 so the data collected at FY3 comprise an average across the previous two years
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no signficant increases in infection intensity following
treatment (although there were some non-signficant
increases) and reductions in infection intensity tended
to increase in magnitude with successive treatment
rounds.
Factors influencing changes in the FOI
Treatment coverage data were collated at the district
level in Uganda and the reported figures were generally
high each year. At baseline, the average therapeutic
coverage in those districts within which the sentinel sites
were located was 83 % (ranging from 63 to 93 %), at FY1
it was 90 % (87–97 %), at FY2 82 % (63–99 %, and at
FY3 86 % (78–98 %).
Results of multivariate regression analyses examining
which programme-relevant factors may influence the
FOI are shown in Table 5. No significant associations be-
tween district-level treatment coverage and the FOI were
observed, or between the cohort follow-up rate (the
retention rate of individuals in the cohort) and the FOI. At
all three time points there was a statistically significant
and positive association between the baseline intensity of
infection and the FOI (FY1: estimate = 0.047, t-value =
6.434, p-value < 0.001; FY2: estimate = 0.022, t-value =
4.487, p-value < 0.001; FY3: estimate = 0.022, t-value =
3.187, p-value = 0.004).
For model selection, the model that best described
the data was selected for each timepoint separately,
using a step function in R to compare AIC values.
For the FOI at FY1, the best fitting model included
only the baseline infection intensity of the cohort (es-
timate = 0.047, t-value = 6.66, p-value < 0.001). The
same situation was found for the FOI at FY2 (esti-
mate = 0.0218, t-value = 4.70, p-value < 0.001) and at
FY3 (estimate = 0.0236, t-value = 3.74, p-value = 0.001).
Changes in intensity of infection
The temporal trends of infection intensity following treat-
ment are shown in Fig. 4. Upon treatment an instantan-
eous reduction in infection is modelled, followed by
reinfection throughout the year prior to the next treat-
ment round. For S. mansoni infections, significant overall
reductions were observed in all countries except in
Tanzania, where the intensity of infection remained stable
throughout the monitored duration of control (for high/
moderate intensity areas; Fig. 4a), or stable after one treat-
ment and reduced after two treatment rounds (low inten-
sity areas; Fig. 4b). Similarly, reductions in the infection
intensity of S. haematobium were observed in all countries
except in those areas of Zambia with a low intensity of in-
fection at baseline, where there was a slight increase fol-
lowing a single round of treatment (Fig. 4d).
Reduction in the prevalence of heavy infection
As a proxy for morbidity, the proportion of individuals
harbouring ‘heavy’ parasite burden (itself measured by egg
load excreted in stool and urine) fell sharply in most areas
(Fig. 5). For S. mansoni there were substantial reductions
in Uganda and Mali, and slight increases in Tanzania,
where it remained around 30 % in high/moderate intensity
areas, and around 0.5 % in low intensity areas. For S. hae-
matobium, the prevalence of heavy infection intensity fell
everywhere, including in Zambia (where there had been
relative increases in the FOI), from 20.5 to 4.8 % in high/
Table 3 Relative (to baseline) changes in the force of infection (FOI) and their 95 % confidence intervals estimated at the point of
monitoring (one or two years) after each round of preventive chemotherapy with praziquantel for Schistosoma haematobium areas
Country BL Infection
Intensity Category
Number in
cohort (n)
BL infection
Intensity (epg)
BL FOI (wppy) FY1 ζ1 FY2 ζ2 FY3 ζ3
[95 % CI] [95 % CI] [95 % CI]
Burkina Faso High 376 124.46 20.03 0.013 [0.0005, 0.12]a 0.124 [0.04, 0.21]a 0.048 [0.02, 0.12]a
Burkina Faso Low 188 17.11 1.69 0.005 [0.0003, 0.14]a 0.253 [0.08, 0.56]a 0.001 [0.0003, 0.10]a
Mali High 591 174.15 9.37 0.27 [0.11, 0.62]a 0.30 [0.11, 0.68]a NA
Mali Low 561 19.67 1.53 0.70 [0.32, 1.34] 0.17 [0.05, 0.44]a NA
Niger High 270 121.87 1.91 0.70 [0.23, 1.42] 0.86 [0.23, 1.88] NA
Niger Low 1047 20.76 0.63 0.18 [0.10, 0.35]a 0.36 [0.21, 0.76]a NA
Tanzania All (Low) 664 11.06 1.22 0.584 [0.22, 0.91]a 0.434 [0.21, 0.80]a
Zambia High 276 89.11 1.53 0.730 [0.21, 1.65] NA NA
Zambia Low 1169 10.01 0.38 2.129 [0.89, 4.21] NA NA
FOI :force of infection expressed as the mean number of adult female parasites acquired per person per year; e/10 ml: eggs per 10 ml of urine; wppy: worms per
person per year; BL: baseline; FY1: follow-up year 1; FY2: follow-up year 2; FY3: follow-up year 3; ζ1, ζ2, ζ3: the relative change in the FOI at FY1, FY2, FY3 respectively,
expressed as a proportion of that at baseline; asignificant decreases in FOI from baseline: NA: not available. In Tanzania there was no treatment or survey at FY2 so the
data collected at FY3 comprise an average across the previous two years. In Burkina Faso there was no treatment following FY1 so the results at FY1 and FY2 constitute
two successive years following a single treatment round
French et al. Parasites & Vectors  (2015) 8:558 Page 10 of 18
moderate intensity areas and from 2.9 to 2.1 % in low in-
tensity areas.
Discussion
The impact of preventative chemotherapy with prazi-
quantel on the level of schistosomiasis infection
intensity, prevalence and morbidity in SCI-assisted pro-
grammes has been published previously (e.g. [2] and ref-
erences therein). In this paper, we assessed the impact
on transmission according to schistosome species, base-
line endemicity level, country (and sentinel site for
Uganda) for six SSA countries that have been assisted by
Table 4 Changes in infection intensity and FOI for each of 32 sentinel sites with longitudinal data collected prior and one year after
praziquantel treatment as part of the monitoring and evaluation component of the Ugandan schistosomiasis control programme
BL infection
intensity Category
District Sentinel Site No. in
cohort (n)
BL FOI
(wppy)
Infection intensity with S. mansoni (epg) Ratio of FOI in relation to BL
BL FY1 FY2 FY3 ζ1 ζ2 ζ3
High Bugiri Buyondo 75 26.97 444.4 59.4a 16.7a 3.5a 0.179a 0.035a 0.015a
Wakawaka 30 30.01 746.3 384.8 539.1 160.0 1.574b 1.698b 0.945
Busia Buloosi 72 24.78 598.1 99.7a 52.4a 24.0a 0.357a 0.220a 0.099a
Hoima Kibiro 57 54.87 1000.3 408.6a 153.7a 247.5a 1.038 0.454a 0.553a
Runga 20 47.35 710.4 404.6 230.4a 110.4a 1.444 0.976 0.727
Tonya 9 61.81 1096.0 228.0a 48.0a 48.0a 0.566 0.088a 0.001a
Masindi Walukubwa 20 62.28 895.2 314.2a 108.9a 974.8 0.591 0.266a 1.346
Mayuge Bugoto LV 45 24.51 616.5 123.1a 61.8a 50.4a 0.484a 0.235a 0.085a
Bwondha 33 28.94 529.5 83.3a 133.8a 61.1a 0.558a 0.604a 0.263a
Nebbi Panyimur 67 31.72 597.6 327.9a 84.6a 49.1a 1.993b 0.121a 0.189a
Medium Bugiri Busiro 57 12.06 154.9 141.4 51.1a 108.5 1.891b 0.572a 1.312
Busia Bwaniha 70 20.38 386.1 58.7a 25.0a 42.7a 0.513a 0.187a 0.251a
Hoima Kasenyi 55 15.46 299.1 347.5 208.9 201.3 1.626b 0.969 1.264
Masindi Butiaba 31 14.32 300.4 98.3 1.5a 27.0a 0.880 0.009a 0.424a
Kabolwa 23 14.59 452.9 43.8a 0.0a 0.0a 0.198a 0.001a 0.001a
Wanseko 57 10.12 114.2 31.2 20.6a 0.0a 0.465a 0.286a 0.000a
Nebbi Kinju 52 15.21 104.4 52.9 16.9a 81.1 1.196 0.444a 1.267
Pokwero 59 4.86 105.8 29.0a 1.7a 0.0a 0.929 0.119a 0.023a
Low Bugiri Kibimba 41 0.36 13.5 16.2 15.4 0.0a 3.584b 2.214b 0.000a
Kibuye 46 3.58 41.7 8.7 16.2 15.7 0.844 1.325 1.817b
Busia Maduwa 77 5.46 68.1 7.0a 3.9a 0.4a 0.772a 0.116a 0.010a
Majanji 64 1.66 27.8 2.2 1.5 0.0 0.064a 0.059a 0.000a
Hoima Kibanjwa 103 0.02 0.2 0.0 0.0 0.0 0.000 0.000 0.000
Mayuge Bukizbu 59 0.40 7.7 0.6a 0.4a 0.0a 0.114a 0.135a 0.000a
Ikulwe 46 0.04 0.5 0.0 0.0 - 0.246 0.000 -
Lwanika 61 5.96 74.5 7.4a 3.5a 44.3 0.292a 0.222a 1.648b
Moyo Aliba 39 1.38 62.2 2.1a 5.7a 2.7a 0.056a 0.244a 0.103a
Dufile 69 1.70 60.5 0.7a 4.1a 0.0a 0.008a 0.151a 0.000a
Etele 71 0.16 7.4 8.7 16.4 0.0a 2.882b 9.789b 0.000a
Laropi 68 1.40 41.6 0.0 1.1 0.0 0.000a 0.052a 0.000a
Obongi 50 0.35 34.1 1.5 0.5 0.0 0.324a 0.10002a 0.000a
Nebbi Pagwaya 54 1.66 49.8 12.0 2.7a 2.1a 0.430a 0.088a 0.087a
BL baseline, FOI force of infection expressed as the mean number of adult female parasites acquired per person per year; wppy: worms per person per year; epg:
eggs per gram of faeces, FY1 follow-up year 1, FY2 follow-up year 2, FY3 follow-up year 3; ζ1, ζ2, ζ3: the relative change in the FOI at FY1, FY2, FY3, respectively, as
a proportion of that at baseline; astatistically significant reduction in infection intensity or FOI from baseline; bstatistically significant increase in infection intensity or FOI
from baseline
Note that the decision to allocate each sentinel site into high, medium, and low infection intensity categories was based on the infection intensity of the overall
school/community at BL, rather than that of the longitudinal cohort selected to be followed up from that school/community (e.g. Kabolwa is classified in the
medium category as the school-level intensity at BL was 339.4 epg; the cohort level was 452.9 epg). Any cohort with fewer than 20 individuals was excluded
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the SCI to implement MDA programmes with
praziquantel.
Representativeness of the SCI longitudinal cohorts
In areas with higher infection intensity, children lost to
follow-up had a significantly higher parasite load than
those who remained in the cohort. These differences
may have been caused by those heavily infected children
being too ill to come back for treatment, being less likely
to be enrolled in schools or having a higher degree of
absenteeism. In Uganda, the higher infection intensity in
those lost to follow-up could also have been caused by
the movement of peripatetic fishing communities who
historically suffer from high infection intensity and
present only occasionally for treatment. Conversely,
where infection levels were higher in the longitudinal
cohort in areas of low endemicity, infected children may
Table 5 Coefficients (and associated p-values) for multivariate linear regression examining the association of programme-relevant
covariates with the force of infection (FOI, measured as the parasite establishment rate). The FOI is estimated following 1, 2, and 3
rounds of praziquantel treatment at follow-up years FY1, FY2, FY3 in Uganda
Covariates Dependent Variable
FY1 FOI FY2 FOI FY3 FOI
Baseline Coverage 16.27 (0.756) 25.40 (0.355) −26.77 (0.721)
Baseline Intensity 0.047 (<0.001) 0.022 (<0.001) 0.022 (0.043)
BL - FY1 Cohort Follow-up Rate −9.502 (0.722) −17.39 (0.282) −5.609 (0.857)
FY1 Coverage - 34.87 (0.473) 11.992 (0.882)
FY1 - FY2 Cohort Follow-up Rate - −0.318 (0.993) −2.807 (0.961)
FY2 Coverage - - 30.972 (0.457)
FY2 - FY3 Cohort Follow-up Rate - - −14.802 (0.287)
a b
c d
Fig. 4 Changes in egg count for each of the countries and endemicity areas under praziquantel treatment in: a and b Schistosoma mansoni
endemic areas (intensity measured as eggs per gram of faeces), and in c and d S. haematobium endemic areas (intensity measured as eggs per
10 ml urine). Data were collected annually. The lines linking the data points are included for illustrative purposes are not verified parasitologically.
These lines assume a constant force of infection and assume 95 % efficacy of treatment for S. mansoni and 99 % efficacy of treatment for
S. haematobium
French et al. Parasites & Vectors  (2015) 8:558 Page 12 of 18
have been more likely to feel unwell and therefore more
likely to seek treatment than their uninfected peers.
There was no difference in cohort retention rate with
host age in Uganda. However, in Burkina Faso older chil-
dren were less likely to return for treatment at each
follow-up year. As older children typically have heavier in-
fections, infection intensity in follow-up years may have
been underestimated, leading to overestimations of the re-
ductions in the FOI, although the differences in follow-up
were small and the age-range relatively narrow.
It may be argued that those individuals recruited into the
SCI cohorts do not represent the wider community because
school-aged children are exposed to more extensive health
messages around avoiding risky water contact. One ap-
proach to overcome this potential bias is to use putatively
untreated 6-year olds recruited into the cohort each year as
a proxy for the community. This approach was attempted
in an earlier paper [21] but was not as useful as expected,
likely due to the uncertainty about their treatment and in-
fection history.
Variation in relative changes of the FOI at broader- and
fine-grain epidemiological levels
Reductions in the FOI relative to baseline values were
observed in most, but not all, combinations of country,
species, endemicity levels, and treatment rounds. Such
reductions will benefit not only those who receive treat-
ment, but also those individuals living in the same area
(or accessing the same transmission site) who do not re-
ceive treatment, including non-enrolled school children
who do not present for treatment, those too young to be
included in MDA programmes, or adults living in an
area receiving school-based treatment only. These bene-
fits are often missed from the evaluation of schistosom-
iasis (and other helminthiases) control programmes
(though see [50]). Exceptions to these reductions are re-
ported for Tanzania (particularly for S. mansoni and S.
haematobium to a lesser extent), and Zambia (for S.
mansoni and S. haematobium in low intensity areas),
where relative increases in the FOI were observed (al-
though the average intensity of infection remained stable
or dropped). The results from the control programme in
Tanzania were affected by very low coverage rates in
some areas (of the order of 10–20 %, unpublished data),
due to adverse publicity against the aims of the control
programme, thought to have been instigated as part of a
politically-motivated campaign [51]. A further possible
explanation is that of treatment failure in these areas.
However, evidence to the contrary is provided by popu-
lation genetic studies of schistosomes from Tanzanian
Fig. 5 Changes in the model-derived estimate of prevalence of heavy infection (S. mansoni ≥400 epg; S. haematobium ≥50e/10 ml) with treatment with
praziquantel. a and b S. mansoni areas; c and d S. haematobium areas. Note difference in y-axis scales. Data were collected annually. The lines linking the
data points are included for illustrative purposes are not verified parasitologically. These lines assume a constant force of infection and assume 95 % efficacy
of treatment for S. mansoni and 99 % efficacy of treatment for S. haematobium
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schools [52], which demonstrated that parasites obtained
from children after treatment were not closely related to
those obtained at baseline, suggesting reinfection rather
than clearance failure. Increases in the FOI were re-
corded in Zambia although the average infection inten-
sity was reduced significantly in the cohorts followed up
for S. mansoni and only increased marginally signifi-
cantly in the S. haematobium cohort. In low intensity
areas, treatment was targeted at school-aged children
only, which will likely lead to a smaller impact on infec-
tion intensity/FOI as only a smaller proportion of the
circulating pool of parasites would be cleared by
praziquantel.
It cannot be discounted that the differences in sam-
pling strategy (e.g. number of Kato Katz slides taken
from a number of stool sample) had an impact on the
estimates of parasite intensity and therefore on changes
in the FOI. This will be the subject of a future analysis.
Considerable heterogeneity in relative changes in the
FOI was also observed at the sentinel site/school level in
Uganda. Possible explanations include variation in epi-
demiological, ecological, programmatic (e.g. levels of
compliance) and locale-specific factors. In addition, vari-
ability will inevitably be introduced by the stochastic na-
ture of the infection process given the smaller size of
these cohorts. The extent of the heterogeneity between
these sites provides a cautionary note to the interpret-
ation of the results of control programmes at a more
macroepidemiological level, i.e. schistosomiasis is funda-
mentally a focal disease. This is particularly important
when examining the impact of control interventions at
the level of transmission zones or contemplating the
possibility of elimination, as the presence of transmission
hot-spots and the possible connectivity between these
through movement of definitive and/or intermediate
hosts may help maintain and resupply the infection [53].
Factors influencing changes in the FOI
The lack of clear relationships between the estimated
FOI and programmatic factors such as treatment cover-
age was perhaps surprising, although this was undoubt-
edly affected by the relatively small range of treatment
coverage observed, its aggregation level (district rather
than school/community), and its dependence on dated
census reports. Further work is required as and when
treatment coverage data become available at a more dis-
aggregated level. In other helminth diseases relying on
MDA for their control (e.g. onchocerciasis), not only are
the levels of therapeutic coverage important, but those
of systematic non-compliance are crucial in influencing
the long-term trends of infection intensity and preva-
lence as shown in modelling studies [54, 55]. However,
the relationship between the FOI and the baseline
endemicity level is interesting and consistent with find-
ings in other helminth infections for which the duration
of treatment necessary to eliminate the infection for
various initial endemicity levels has been investigated
[56].
Model structure and parasite biology
Worm lifespan is a parameter that plays a key role in
driving the outcomes of the model; the shorter the life-
span the higher the corresponding estimates of the FOI,
yet there is still significant uncertainty as to the value for
this parameter, with 2 to 10 years often quoted as a
plausible range for the mean life span [3, 4]. However,
some reported cases of infection (in the absence of re-
infection) exceed 30 years [57, 58], suggesting that the
distribution may be heavily right-skewed. Studies to elu-
cidate the patterns of worm lifespan are required [59],
not just in terms of average age, but also the shape of
the distribution of worm ages. This will be important to
consider for any future elimination programmes in order
to predict the required length of control interventions
(e.g. vector control, chemotherapy), as has been the case
in other helminth infections such as lymphatic filariasis
[60] and onchocerciasis [61, 62], particularly in view of
the fact that schistosomiasis programmes are starting to
consider elimination of the infection as a goal [63, 64].
There are likely to be density-dependent processes op-
erating on the worm’s lifecycle, such as mating probabil-
ity, parasite establishment (via acquired immunity
elicited by established worms), and parasite fecundity. A
reduction in parasite intensity following treatment will
lead to a relaxation of the negative density-dependent
processes (an increase in the per-capita establishment or
reproductive success of the parasite), and therefore
smaller reductions in FOI than might otherwise be ex-
pected. The modelling approach utilised here defines the
FOI in terms of the number of worms which establish
per host per unit time which encapsulates all of the
above processes (as has also been utilised in onchocer-
ciasis studies [65], rather than in terms of the host’s
exposure to parasite transmission stages, which is some-
times referred to as the transmission potential [66, 67].
We contend that this definition is more useful for mor-
bidity control programmes as it is the established worms
that drive morbidity and onward transmission, rather
than the parasites to which hosts are exposed.
We still have an incomplete understanding of how the
immunity of human hosts influences the rate of reinfec-
tion following treatment. Therefore, changes in FOI need
to be interpreted carefully. The reduced rate of reinfec-
tion following treatment could be explained either
through a decrease in environmental transmission or a
decrease in the treated host population’s susceptibility to
reinfection. PZQ treatment is known to release somatic
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parasite antigens which may elicit protective responses
that facilitate resistance to reinfection. However, it is far
from clear how much this immunological response may
influence the rate of Schistosoma establishment, develop-
ment, or fecundity.
Parasite ‘strains’ and hybridization
There is an increasing body of evidence for the existence
of some degree of within-species differentiation in the
Schistosoma genus. Differing phenotypes and genotypes
of parasites have been reported as occurring in different
regions of SSA (for S. mansoni [68, 69], for S. haemato-
bium [69–71] and for S. japonicum [72]). It is likely that
such parasite ‘strains’ may vary in their susceptibility to
praziquantel. Epidemiological and ecological conditions,
such as water-contact behaviour, the resilience of snail
intermediate hosts to environmental perturbations, and
the extent and permanence of water bodies will inevit-
ably differ between areas. In addition, secular changes
such as rainfall patterns; water and sanitation pro-
grammes; human population distribution and migration;
patterns of coinfection; and the motivation and experi-
ence of the programme staff will all affect the success of
a control programme. These all constitute examples of
the challenges in translating what are undoubtedly clin-
ically efficacious interventions into effective community-
level programmes [73].
Allayed to this is the issue of hybridization between schis-
tosome parasite species, often between human and non-
human schistosome species. There is reported evidence of
natural hybridization between S. haematobium and the live-
stock species S. bovis in Senegal [74], between S. haemato-
bium and S. guineensisin Cameroon [75, 76], between S.
haematobium and S. curassoni of livestock in Senegal [77],
between S. mansoni and the rodent parasite S. rodhaini in
Kenya [78], and of mating interactions between S. mansoni
and S. haematobium in hamster models [79]. Additionally,
co-infection of S. mansoni and S. haematobium has been
found to have an impact on the infectivity and morbidity of
single versus mixed infections [80–82].
Control versus elimination
Although annual praziquantel treatment resulted, in the
majority of areas, in relative reductions in the FOI, in the
absence of on-going treatment and/or measures that more
permanently reduce exposure, parasite acquisition and in-
fection intensity will likely return towards baseline values.
Recently there has been an increased focus on elimination
of schistosomiasis using a combination of intervention
strategies, such as has occurred in Morocco [83, 84], Japan
[85], and in large areas of China [86]. How feasible elimin-
ation of infection is in the transmission heartland of SSA
is less certain. However, there are now programmes that
aim to identify the kinds of integrated strategies (such as
MDA, water and sanitation improvement, and com-
prehensive health education messages) that are
needed to eliminate schistosomiasis in SSA, particu-
larly in more isolated foci such as on the Unguja is-
land of Zanzibar [63, 64].
The results from the models presented here can help
towards this end by identifying areas where MDA alone
may be sufficient to push transmission below thresholds
of no return (known as transmission breakpoints [10,
11]), or more pragmatically, below operational thresh-
olds for elimination that would indicate the cessation of
MDA and the commencement of post-MDA surveil-
lance. This approach has been taken in other helminthi-
ases such as onchocerciasis to identify, through
modelling studies, epidemiological scenarios that would
require annual or biannual MDA, or the addition of
other complementary interventions [55, 87]. We advo-
cate that further modelling work be conducted, includ-
ing the development of stochastic frameworks, to
examine the effect of multiple interventions and of mul-
tiple hosts [88] that could be deployed concurrently or
in staggered regimes, and to identify transmission break-
points in each area, as well as the impact of chance
events such as stochastic fade-out.
Conclusions
Significant reductions in the FOI compared to baseline
values, as estimated using a schistosomiasis transmission
model, were reported in many, but not all, of the SCI co-
horts across SSA for both S. mansoni and S. haematobium
infections following successive rounds of praziquantel
treatment. These reductions will benefit those individuals
who receive treatment as well as those who do not, an as-
pect of MDA that is often missed from its analysis and ad-
vocacy, and which is crucial for the quantification of the
cost effectiveness of interventions [89]. A wide range of
values were observed, likely reflecting the locale-specific
ecological, epidemiological, and programmatic conditions,
such as the differing approaches to implementation and
successes of the various countries’ control programmes.
Changes in the FOI at a finer scale also showed great het-
erogeneity, reflecting the focality of schistosomiasis trans-
mission, and the stochastic nature of the infection
process. The application of transmission dynamics
models, fitted to longitudinal M&E data, constitutes a
helpful tool in the evaluation of large-scale schistosomiasis
control and elimination programmes.
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